Investigation and pending class action lawsuit against Pfizer on behalf of a proposed class of direct purchasers of the brand-name prescription drug Neurontin.
The class action lawsuit alleges that Pfizer, Inc., one of the nation's largest pharmaceutical manufacturers, and its subsidiary Warner-Lambert Co., illegally maintained a monopoly in the market for Neurontin, a popular anti-epilepsy drug, by filing sham patent litigation against generic competitors in order to delay the marketing of less expensive generic substitutes for Neurontin.
The lawsuit alleges that, as a result, all purchasers paid artificially inflated prices for the Neurontin drug entity. The class action lawsuit would include all entities that purchased Neurontin directly from Pfizer between January 16, 2000 and the present.
Do not change medications without first consulting your doctor.